(NASDAQ:QNRX) Shares are up more than 39% in pre market trading. Currently at $.86 cents on the Nasdaq. More than 1500 shares have traded hands.

Skinvisible, Inc.  is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ:QNRX), has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formulation which uses Skinvisible’s Invisicare® proprietary drug delivery technology. The topical formulation “QRX003” was developed to treat Nethertons Syndrome, a debilitating hereditary disorder that affects the skin, hair and the immune system. There currently is no cure or approved treatment for Netherton Syndrome.

https://www.digitaljournal.com/pr/skinvisible-announces-first-invisicare-delivery-technology-product-to-receive-u-s-fda-acceptance-of-investigational-new-drug

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist